Page last updated: 2024-10-22

albuterol and Cardiovascular Diseases

albuterol has been researched along with Cardiovascular Diseases in 19 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease."2.76Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. ( Cicale, MJ; Cockcroft, JR; Coxson, HO; Crater, GD; Dransfield, MT; Emmett, AH; Martinez, FJ; Rubin, DB; Sharma, SS; Townsend, RR, 2011)
"Previous studies have suggested that long-term use of beta agonists to treat chronic obstructive pulmonary disease (COPD) may increase the risk of cardiovascular adverse events."2.75Cardiovascular events in patients with COPD: TORCH study results. ( Anderson, JA; Calverley, PM; Celli, B; Crim, C; Ferguson, GT; Jenkins, C; Jones, PW; Vestbo, J; Willits, LR; Yates, JC, 2010)
"Treatment with salmeterol, 50 micro g bid, showed no increased risk of cardiovascular adverse events (AEs) compared with placebo (relative risk, 1."2.71Cardiovascular safety of salmeterol in COPD. ( Darken, P; Ferguson, GT; Fischer, T; Funck-Brentano, C; Reisner, C, 2003)
"Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality."2.43Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. ( Cazzola, M; Donner, CF; Matera, MG, 2005)
" Adverse events (AEs) were analysed overall and according to Anti-Platelet Trialists' Collaboration (APTC) criteria and baseline cardiovascular risk factors."1.37Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. ( Chung, KF; Felser, JM; Hu, H; Rueegg, P; Worth, H, 2011)
"To compare the risk of total mortality and certain respiratory and cardiac adverse events among users of the two types of recommended long-acting bronchodilators, we conducted a cohort study."1.34Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. ( Jara, M; Kesten, S; Lanes, SF; May, C; Wentworth, C, 2007)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.26)18.2507
2000's8 (42.11)29.6817
2010's10 (52.63)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Moore, LE2
Kapoor, K1
Byers, BW2
Brotto, AR1
Ghods-Esfahani, D1
Henry, SL1
St James, RB1
Stickland, MK2
Kelly, A1
Kennedy, A1
John, BM1
Duane, B1
Lemanowicz, J1
Little, J1
Jones, A1
Vennelle, M1
Connell, M1
McKillop, G1
Newby, DE1
Douglas, NJ1
Riha, RL1
Edgell, H1
Chung, C1
Calaghan, S1
Kozera, L1
White, E1
Richie, RC1
Płusa, T1
Calverley, PM1
Anderson, JA1
Celli, B1
Ferguson, GT2
Jenkins, C1
Jones, PW1
Crim, C1
Willits, LR1
Yates, JC1
Vestbo, J1
Worth, H1
Chung, KF1
Felser, JM1
Hu, H1
Rueegg, P1
Dransfield, MT1
Cockcroft, JR1
Townsend, RR1
Coxson, HO1
Sharma, SS1
Rubin, DB1
Emmett, AH1
Cicale, MJ1
Crater, GD1
Martinez, FJ1
Oba, Y1
Ruel, G1
Lapointe, A1
Pomerleau, S1
Couture, P1
Lemieux, S1
Lamarche, B1
Couillard, C1
Funck-Brentano, C1
Fischer, T1
Darken, P1
Reisner, C1
Cazzola, M1
Matera, MG1
Donner, CF1
Jara, M1
Lanes, SF1
Wentworth, C1
May, C1
Kesten, S1
Staudinger, HW1
Haas, JF1
Colin, P1
Berdeaux, A1
Lipworth, BJ1
Burggraaf, J1
Westendorp, RG1
in't Veen, JC1
Schoemaker, RC1
Sterk, PJ1
Cohen, AF1
Blauw, GJ1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered[NCT00268216]Phase 36,228 participants (Actual)Interventional2000-09-30Completed
A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) i[NCT00463567]Phase 2/Phase 32,059 participants (Actual)Interventional2007-04-30Completed
A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol ([NCT00567996]Phase 31,002 participants (Actual)Interventional2007-11-30Completed
A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary D[NCT00393458]Phase 31,732 participants (Actual)Interventional2006-10-31Completed
A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)[NCT00857766]Phase 4249 participants (Actual)Interventional2009-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"The Percentage of Days of Poor Control Reported Over the 26 Week Treatment Period"

"A Chronic Obstructive Pulmonary Disease (COPD) day of poor control was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of days of poor control as well as FEV1 reversibility components as covariates." (NCT00463567)
Timeframe: up to 26 weeks

InterventionPercentage of days (Least Squares Mean)
Indacaterol 150 µg (Continued Into Stage 2)31.5
Indacaterol 300 µg (Continued Into Stage 2)30.8
Tiotropium (Continued Into Stage 2)31.0
Placebo (Continued Into Stage 2)34.0

Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 1 Hour to 4 Hour Post Morning Dose After 2 Weeks of Treatment

"Interim Analysis: Stage 1.~Spirometry was conducted according to internationally accepted standards. Standardized with respect to time (AUC 1h-4h) for FEV1 measurements taken from 1 hour to 4 hour post morning dose on Day 14. Standardized FEV1 AUC was calculated by the trapezoidal rule. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates." (NCT00463567)
Timeframe: Day 14, After 2 Weeks of treatment in Stage 1

InterventionLiters (Least Squares Mean)
Indacaterol 150 µg1.53
Indacaterol 300 µg1.58
Tiotropium 18 µg1.49
Placebo1.30
Indacaterol 75 µg1.50
Indacaterol 600 µg1.53
Formoterol 12 µg1.52

Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment

FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates. (NCT00463567)
Timeframe: after 12 weeks of treatment

InterventionLiters (Least Squares Mean)
Indacaterol 150 µg (Continued Into Stage 2)1.46
Indacaterol 300 µg (Continued Into Stage 2)1.46
Tiotropium 18 µg (Continued Into Stage 2)1.42
Placebo (Continued Into Stage 2)1.28

Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 2 Weeks of Treatment

"Interim Analysis: Stage 1.~Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates." (NCT00463567)
Timeframe: Day 15, After 2 Weeks of treatment in Stage 1

InterventionLiters (Least Squares Mean)
Indacaterol 150 µg1.49
Indacaterol 300 µg1.52
Tiotropium 18 µg1.45
Placebo1.31
Indacaterol 75 µg1.46
Indacaterol 600 µg1.51
Formoterol 12 µg1.42

"Percentage of COPD Days of Poor Control During 26 Weeks of Treatment"

"Participants rated their symptoms on a scale of 0=none to 3=severe. A Chronic Obstructive Pulmonary Disease (COPD) day of poor control was defined as any day in the participants diary with a score >=2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). The mixed model used baseline percentage of days of poor control, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates." (NCT00567996)
Timeframe: Up to 26 weeks

InterventionPercentage of days (Least Squares Mean)
Indacaterol 150 μg34.1
Salmeterol 50 μg34.1
Placebo38.1

St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 Weeks of Treatment

SGRQ is a health related quality of life questionnaire consisting of 76 items in three sections: symptoms, activity and impacts. The total score is 0 to 100 with a higher score indicating poorer health status. The mixed model used baseline SGRQ total score, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates. (NCT00567996)
Timeframe: Week 12

InterventionScore on a scale (Least Squares Mean)
Indacaterol 150 μg36.4
Salmeterol 50 μg38.5
Placebo42.6

Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment

Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates. (NCT00567996)
Timeframe: Week 12

InterventionLiters (Least Squares Mean)
Indacaterol 150 μg1.45
Salmeterol 50 μg1.39
Placebo1.28

Percentage of Days of Poor Control During 52 Weeks of Treatment

Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates. (NCT00393458)
Timeframe: Baseline to end of study (Week 52)

InterventionPercentage of days (Least Squares Mean)
Indacaterol 300 μg Plus Placebo to Formoterol33.6
Indacaterol 600 μg Plus Placebo to Formoterol30.0
Formoterol 12 μg Plus Placebo to Indacaterol33.5
Placebo to Indacaterol Plus Placebo to Formoterol38.3

Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85

FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates. (NCT00393458)
Timeframe: Week 12 + 1 day, Day 85

InterventionLiters (Least Squares Mean)
Indacaterol 300 μg Plus Placebo to Formoterol1.48
Indacaterol 600 μg Plus Placebo to Formoterol1.48
Formoterol 12 μg Plus Placebo to Indacaterol1.38
Placebo to Indacaterol Plus Placebo to Formoterol1.31

Mean Change From Baseline in Aortic Pulse Wave Velocity (aPWV) at the 12-Week Endpoint

The 12-week Endpoint is defined as the last scheduled measurement of PWV during the 12-week double-blind treatment period (from Visits 3-5; Weeks 4, 8, and 12, respectively), and Baseline is defined as the PWV measure from Visit 2 (Randomization). Change from Baseline was calculated as the Endpoint value minus the Baseline Value. PWV is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the PW along an artery is dependent on the stiffness of that artery. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)

,
Interventionmeters per second (m/s) (Mean)
Baseline, n=118, 12212-Week Endpoint, n=113, 110Change from Baseline
FSC DISKUS 250/50 mcg10.069.83-0.24
Matching Placebo9.879.950.13

Mean Change From Baseline in Augmentation Index (AIx) at the 12-Week Endpoint

AIx is a surrogate measure of peripheral (not aortic) arterial resistance and is measured by analysis of the pulse wave at the radial artery. AIx = ([delta P/Pulse Pressure] x 100); delta P is defined by a notch near the peak of the pulse wave. Change from Baseline was calculated as the Endpoint value minus the Baseline Value. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)

,
Intervention% of total height of peak pulse pressure (Mean)
Baseline, n=121, 12212-Week Endpoint, n=114, 111Change from Baseline
FSC DISKUS 250/50 mcg27.927.2-0.7
Matching Placebo27.827.6-0.4

Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at the 12-Week Endpoint

FEV1 is a measure of air flow via spirometry. Change from Baseline was calculated as the Endpoint value minus the Baseline Value. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)

,
Interventionmilliliters (Mean)
Baseline, n=123, 12512-Week Endpoint, n=105, 102Change from Baseline
FSC DISKUS 250/50 mcg14441588136
Matching Placebo14801500-3

Reviews

1 review available for albuterol and Cardiovascular Diseases

ArticleYear
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
    Drugs, 2005, Volume: 65, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2005

Trials

6 trials available for albuterol and Cardiovascular Diseases

ArticleYear
The effect of continuous positive airway pressure therapy on arterial stiffness and endothelial function in obstructive sleep apnea: a randomized controlled trial in patients without cardiovascular disease.
    Sleep medicine, 2013, Volume: 14, Issue:12

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Aorta; Blood Flow Velocity; Cardiovascular Di

2013
Cardiovascular events in patients with COPD: TORCH study results.
    Thorax, 2010, Volume: 65, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Bronchodilator

2010
Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:9

    Topics: Albuterol; Androstadienes; Arteries; Blood Flow Velocity; Cardiovascular Diseases; Double-Blind Meth

2011
Evidence that cranberry juice may improve augmentation index in overweight men.
    Nutrition research (New York, N.Y.), 2013, Volume: 33, Issue:1

    Topics: Adult; Albuterol; Beverages; Blood Pressure; Cardiovascular Diseases; Cardiovascular Physiological P

2013
Cardiovascular safety of salmeterol in COPD.
    Chest, 2003, Volume: 123, Issue:6

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cardiovas

2003
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients.
    Thorax, 2001, Volume: 56, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma

2001

Other Studies

12 other studies available for albuterol and Cardiovascular Diseases

ArticleYear
Acute effects of salbutamol on systemic vascular function in people with asthma.
    Respiratory medicine, 2019, Volume: 155

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Blood Pre

2019
A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:5

    Topics: Adolescent; Albuterol; Bronchoconstriction; Bronchodilator Agents; Cardiovascular Diseases; Child; C

2013
Short-term cardiovascular and autonomic effects of inhaled salbutamol.
    Respiratory physiology & neurobiology, 2016, Volume: 231

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Arterial Pressure

2016
Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte.
    Journal of molecular and cellular cardiology, 2008, Volume: 45, Issue:1

    Topics: Actin Cytoskeleton; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animal

2008
Assessing mortality risk in COPD.
    Journal of insurance medicine (New York, N.Y.), 2008, Volume: 40, Issue:1

    Topics: Actuarial Analysis; Albuterol; Androstadienes; Body Mass Index; Bronchial Hyperreactivity; Bronchodi

2008
[Agonists of beta2 adrenergic receptor in the therapy of obstructive diseases].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2010, Volume: 28, Issue:163

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Arrhythmias, Cardiac; Card

2010
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:4

    Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol

2011
Tiotropium versus salmeterol in COPD.
    The New England journal of medicine, 2011, 06-30, Volume: 364, Issue:26

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; C

2011
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.
    Drug safety, 2007, Volume: 30, Issue:12

    Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Cardio

2007
Extrapulmonary effects of fenoterol compared to salbutamol in asthmatics.
    Respiratory medicine, 1993, Volume: 87, Issue:8

    Topics: Albuterol; Asthma; Cardiovascular Diseases; Drug Administration Schedule; Fenoterol; Humans

1993
[Beta-adrenergic agonists (adrenaline, dopamine, dobutamine, salbutamol), beta-blockers. Principles and regulations of use].
    La Revue du praticien, 2001, Feb-28, Volume: 51, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Cardiovascular Diseases; Dobutamine; Dopamine; Epinephrine; Hum

2001
Revisiting interactions between hypoxaemia and beta2 agonists in asthma.
    Thorax, 2001, Volume: 56, Issue:7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Cardiovascular Diseases; Dose-Response Relationship, Dr

2001